ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells
and slow the growth of glioblastoma multiforme.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have
glioblastoma multiforme in first relapse.